Tenofovir/Levonorgestrel

替诺福韦/左炔诺孕酮

Report date: 2024/11/13 20:00:43

Base Information

Drug NameTenofovir/Levonorgestrel
Drug Alias Nametenofovir + levonorgestrel左炔诺孕酮+替诺福韦Levonorgestrel/Tenofovir左炔诺孕酮/替诺福韦Levonorgestrel+Tenofovir +[6] 
ClassificationSmall molecules > SteroidsSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionProgesterone receptor agonistsReverse transcriptase inhibitors
TargetsReverse transcriptaseProgesterone receptor
Therapy Area/IndicationsContraceptionRetroviridae InfectionsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryKenya
CombinationsYes TenofovirLevonorgestrel
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNorthwest UniversityContraceptive Research And Development Organization
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKenya Medical Research InstituteUniversity Of Washington
Active IndicationsN/A
Inactive IndicationsContraceptionRetroviridae InfectionsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A